Organogenesis (NASDAQ:ORGO) Shares Gap Up - Here's What Happened

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $5.42, but opened at $5.56. Organogenesis shares last traded at $5.20, with a volume of 239,503 shares changing hands.

Analyst Ratings Changes

Separately, Morgan Stanley upped their target price on Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th.

Organogenesis Stock Down 3.6 %

The stock has a 50-day moving average of $4.21 and a 200 day moving average of $3.58. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $570.73 million, a PE ratio of -75.00 and a beta of 1.66.

Insider Transactions at Organogenesis

In other news, Director Michael Joseph Driscoll sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the completion of the sale, the director now owns 166,879 shares in the company, valued at $851,082.90. This trade represents a 13.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 36.90% of the company's stock.

Institutional Trading of Organogenesis

Several hedge funds have recently made changes to their positions in the company. Intech Investment Management LLC bought a new stake in Organogenesis in the 3rd quarter valued at about $43,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Organogenesis by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company's stock valued at $2,713,000 after buying an additional 23,675 shares in the last quarter. FMR LLC boosted its holdings in Organogenesis by 34.2% in the 3rd quarter. FMR LLC now owns 173,595 shares of the company's stock worth $496,000 after buying an additional 44,199 shares during the period. Captrust Financial Advisors purchased a new position in Organogenesis in the 3rd quarter valued at approximately $36,000. Finally, Verition Fund Management LLC raised its holdings in Organogenesis by 542.8% during the 3rd quarter. Verition Fund Management LLC now owns 78,690 shares of the company's stock valued at $225,000 after acquiring an additional 66,448 shares during the period. 49.57% of the stock is currently owned by institutional investors.

Remove Ads

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.